To the full analysis
Evolent Health stock: growth
EVHEvolent Health reported $1.88B in revenue for fiscal 2025, down 26.6% on the prior year, up 15.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
51.7%
per year from 2012 to 2025, per share 39.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 15.2% | 34.5% | 51.7% |
| Revenue per share | 8.6% | 21.5% | 39.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $8.35M | −$19.26M | −$15.1M |
| 2013 | $25.67M | $20.02M | −$24.07M |
| 2014 | $0 | −$25.25M | −$86.13M |
| 2015 | $96.88M | $332.49M | −$26.34M |
| 2016 | $254.19M | −$159.74M | −$51.04M |
| 2017 | $434.95M | −$60.67M | −$55.81M |
| 2018 | $627.06M | −$52.66M | −$60.2M |
| 2019 | $687.12M | −$301.97M | −$78.18M |
| 2020 | $924.64M | −$334.25M | −$45.7M |
| 2021 | $907.96M | −$37.6M | $13.76M |
| 2022 | $1.35B | −$19.16M | −$49.91M |
| 2023 | $1.96B | −$113.04M | $113.84M |
| 2024 | $2.55B | −$61.62M | −$6.13M |
| 2025 | $1.88B | −$534.51M | $4.76M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2016)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.